Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Search research articles

Related Experiment Videos

Chronic myelomonocytic leukemia.

A M Storniolo¹, W C Moloney, D S Rosenthal

¹Department of Medicine, University of California, San Diego, LaJolla.

|November 1, 1990

Summary

This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

TBCRC 035: randomized phase II pharmacodynamic study of standard and reduced-dose palbociclib with endocrine therapy in hormone receptor (HR)-positive previously treated metastatic breast cancer.

ESMO open·2026

Same author

Improvements in Survival and Clinical Benefit With Gemcitabine as First-Line Therapy for Patients With Advanced Pancreas Cancer: A Randomized Trial.

Journal of clinical oncology : official journal of the American Society of Clinical Oncology·2023

Same author

Factors underlying metastatic breast cancer patients' perceptions of symptom importance: a qualitative analysis.

European journal of cancer care·2016

Same author

Aromatase inhibitor-induced modulation of breast density: clinical and genetic effects.

British journal of cancer·2013

Same author

Plasma letrozole concentrations in postmenopausal women with breast cancer are associated with CYP2A6 genetic variants, body mass index, and age.

Clinical pharmacology and therapeutics·2011

Same author

Inflammatory cytokines and aromatase inhibitor-associated musculoskeletal syndrome: a case-control study.

British journal of cancer·2010

Prognostic factors for chronic myelomonocytic leukemia (CMML) were studied. Marrow blast percentage significantly impacts survival, with higher percentages indicating a poorer prognosis for CMML patients.

Area of Science:

Hematology
Oncology

Background:

Chronic myelomonocytic leukemia (CMML) is a clonal hematopoietic stem cell disorder.
Identifying prognostic factors is crucial for managing CMML and predicting patient outcomes.

Purpose of the Study:

To evaluate prognostic factors influencing acute leukemia conversion and survival in adult CMML patients.
To determine the correlation between specific clinical parameters and patient survival.

Main Methods:

Retrospective analysis of 30 adult patients diagnosed with CMML.
Evaluation of factors including leukocyte count, monocyte count, and bone marrow blast percentage.

Main Results:

Neither leukocyte count nor monocyte count showed a correlation with survival.

Related Experiment Videos

Median survival for all patients was 41 months.

Patients with <5% marrow blasts had a median survival of 60 months, versus 9 months for those with 5-20% blasts.

Conclusions:

Bone marrow blast percentage is a significant prognostic factor in CMML.
Higher marrow blast percentages are associated with significantly shorter survival in CMML patients.